GlaxoSmithKline plc (GSK) announced that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Tyverb (lapatinib) in combination with paclitaxel for the treatment of patients with metastatic breast cancer whose tumours over-express HER2 (ErbB2).

Tyverb/Tykerb is approved in over 90 countries including the EU, Switzerland, US, Canada, Japan, Australia and countries in South America and Asia.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.